ERBB2 and breast cancer: HER-2+ breast cancer is highly malignant and has a poor prognosis; however, the latter has been significantly improved with the availability of trastuzumab, which has been widely reported to improve the pCR rate from 30.3% to 65% when used as part of a NAC regimen [8–11].